Zurich Cantonal Bank
LCTX icon

Zurich Cantonal Bank’s Lineage Cell Therapeutics LCTX Stock Holding History

Zurich Cantonal Bank’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,234
Closed -$7K – 2618
2019
Q1 		$7K Hold
5,234
– – ﹤0.01% 2539
2018
Q4 		$5K Sell
5,234
-748
-13% -$1.15K ﹤0.01% 2575
2018
Q3 		$12K Hold
5,982
– – ﹤0.01% 2531
2018
Q2 		$11K Hold
5,982
– – ﹤0.01% 2482
2018
Q1 		$14K Hold
5,982
– – ﹤0.01% 2463
2017
Q4 		$11K Buy
+5,982
New +$13.1K ﹤0.01% 2485

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Zurich Cantonal Bank's LCTX Position: Q2 2019 in Review

Zurich Cantonal Bank sold out of Lineage Cell Therapeutics (LCTX) in Q2 2019, closing a stake of 5,234 shares — an estimated $7K sold.

Zurich Cantonal Bank first reported a position in LCTX in Q4 2017 and held it in 6 quarters. The position peaked at $14K in Q1 2018. 107 funds tracked by Wall St. Rank hold LCTX as of Q2 2019.

  • Zurich Cantonal Bank reported no remaining Lineage Cell Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Zurich Cantonal Bank sold 5,234 Lineage Cell Therapeutics shares in Q2 2019, an estimated $7K.
  • Zurich Cantonal Bank first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 6 quarters.
  • Zurich Cantonal Bank's Lineage Cell Therapeutics position peaked at $14K in Q1 2018.
  • 107 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2019.

Based on Zurich Cantonal Bank's 13F filing for Q2 2019, filed 30 Jul 2019.